Literature DB >> 15795276

Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline.

Yoav Peretz1, Galit Alter, Marie-Pierre Boisvert, George Hatzakis, Christos M Tsoukas, Nicole F Bernard.   

Abstract

Immune responses to human immunodeficiency virus (HIV) are detected at all stages of infection and are believed to be responsible for controlling viremia. This study seeks to determine whether gamma interferon (IFN-gamma)-secreting HIV-specific T-cell responses influence disease progression as defined by the rate of CD4 decline. The study population consisted of 31 subjects naive to antiretroviral therapy. All were monitored clinically for a median of 24 months after the time they were tested for HIV-specific responses. The rate of CD4+-T-cell loss was calculated for all participants from monthly CD4 counts. Within this population, 17 subjects were classified as typical progressors, 6 subjects were classified as fast progressors, and 8 subjects were classified as slow progressors. Peripheral blood mononuclear cells were screened for HIV-specific IFN-gamma responses to all expressed HIV genes. Among the detected immune responses, 48% of the recognized peptides were encoded by Gag and 19% were encoded by Nef gene products. Neither the breadth nor the magnitude of HIV-specific responses correlated with the viral load or rate of CD4 decline. The breadth and magnitude of HIV-specific responses did not differ significantly among typical, fast, and slow progressors. These results support the conclusion that although diverse HIV-specific IFN-gamma-secreting responses are mounted during the asymptomatic phase, these responses do not seem to modulate disease progression rates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795276      PMCID: PMC1069552          DOI: 10.1128/JVI.79.8.4908-4917.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?

Authors:  Zvi Grossman; Martin Meier-Schellersheim; Ana E Sousa; Rui M M Victorino; William E Paul
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

2.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.

Authors:  Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

4.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

Authors:  David H O'Connor; Todd M Allen; Thorsten U Vogel; Peicheng Jing; Ivan P DeSouza; Elizabeth Dodds; Edward J Dunphy; Cheri Melsaether; Bianca Mothé; Hiroshi Yamamoto; Helen Horton; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

5.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

6.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

7.  Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Authors:  Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark J Mulligan; Paul A Goepfert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.

Authors:  Matilu Mwau; Andrew J McMichael; Tomás Hanke
Journal:  AIDS Res Hum Retroviruses       Date:  2002-06-10       Impact factor: 2.205

10.  HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism.

Authors:  R T Gandhi; B K Chen; S E Straus; J K Dale; M J Lenardo; D Baltimore
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

View more
  8 in total

1.  Changes in function of HIV-specific T-cell responses with increasing time from infection.

Authors:  Michel L Ndongala; Philomena Kamya; Salix Boulet; Yoav Peretz; Danielle Rouleau; Cécile Tremblay; Roger Leblanc; Pierre Côté; Jean-Guy Baril; RéJean Thomas; Sylvie Vézina; Mohamed R Boulassel; Jean-Pierre Routy; Rafick P Sékaly; Nicole F Bernard
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

2.  A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses.

Authors:  Salix Boulet; Michel L Ndongala; Yoav Peretz; Marie-Pierre Boisvert; Mohamed-Rachid Boulassel; Cecile Tremblay; Jean-Pierre Routy; Rafick-P Sekaly; Nicole F Bernard
Journal:  J Immunol Methods       Date:  2006-12-29       Impact factor: 2.303

3.  Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus.

Authors:  Julie A Terwee; Jennifer K Carlson; Wendy S Sprague; Kerry S Sondgeroth; Sarah B Shropshire; Jennifer L Troyer; Sue VandeWoude
Journal:  Virology       Date:  2008-05-22       Impact factor: 3.616

4.  Human leucocyte antigen-Bw4 and Gag-specific T cell responses are associated with slow disease progression in HIV-1B-infected anti-retroviral therapy-naive Chinese.

Authors:  W-H Li; C-Y Li; H-B Yang; H-P Zhang; X Zhang; L-S Kong; X-N Xu; S-C Lu; H-P Yan
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

5.  Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption.

Authors:  Kenneth H Huang; Marie-Pierre Boisvert; Famane Chung; Maude Loignon; Don Zarowny; Lise Cyr; Emil Toma; Nicole F Bernard
Journal:  J Immune Based Ther Vaccines       Date:  2006-11-28

Review 6.  Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.

Authors:  Marcel Tongo; Wendy A Burgers
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

7.  A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function.

Authors:  Avantika S Chitre; Michael G Kattah; Yenny Y Rosli; Montha Pao; Monika Deswal; Steven G Deeks; Peter W Hunt; Mohamed Abdel-Mohsen; Luis J Montaner; Charles C Kim; Averil Ma; Ma Somsouk; Joseph M McCune
Journal:  PLoS Pathog       Date:  2018-03-05       Impact factor: 6.823

8.  Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.

Authors:  Jennifer Serwanga; Leigh Anne Shafer; Edward Pimego; Betty Auma; Christine Watera; Samantha Rowland; David Yirrell; Pietro Pala; Heiner Grosskurth; Jimmy Whitworth; Frances Gotch; Pontiano Kaleebu
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.